A Phase 2b dose-ranging study of galvokimig in adults with atopic dermatitis
Research type
Research Study
Full title
A multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of galvokimig in adult study participants with moderate to severe atopic dermatitis
IRAS ID
1013200
Contact name
Jasmine Sacré
Contact email
Sponsor organisation
UCB Biopharma SRL
Clinicaltrials.gov Identifier
Research summary
Researchers are looking for a better way to treat atopic dermatitis. Atopic dermatitis, also called eczema, is a long-term condition that causes the skin to become dry, itchy, and cracked. On paler coloured skin, atopic dermatitis can look red. On darker coloured skin, atopic dermatitis can look grey or purple. It can affect any area of the skin, but it is more common in areas such as the inside of the elbows, behind the knees, and on the face and neck. The exact cause of eczema is unknown, but it tends to run in families. It can be triggered by allergies, stress, dry skin, and infection. Researchers think atopic dermatitis happens when the body’s defence system (the immune system) reacts too strongly, and the skin can't protect it the way it should. This makes the skin itchy, red, and easy to irritate.
Researchers want to learn if a new treatment called galvokimig can help people with moderate to severe eczema. Galvokimig is a biologic and designed to work by stopping certain proteins of the immune system from working. The immune system is the body’s natural defence system. These proteins are called interleukin- 13 (IL-13) and interleukin-17 (IL-17), and they are known to cause inflammation or swelling that can lead to eczema. Researchers think that by stopping IL-13 and IL-17 from working, people could have less inflammation and an improvement in their eczema.
REC name
South Central - Oxford B Research Ethics Committee
REC reference
26/SC/0005
Date of REC Opinion
5 Feb 2026
REC opinion
Further Information Favourable Opinion